Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2002 Apr;86(4):286–290. doi: 10.1136/adc.86.4.286

Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research

P Brogan 1, A Bose 1, D Burgner 1, D Shingadia 1, R Tulloh 1, C Michie 1, N Klein 1, R Booy 1, M Levin 1, M Dillon 1
PMCID: PMC1719139  PMID: 11919108

Abstract

This article proposes a clinical guideline for the diagnosis and treatment of Kawasaki disease in the UK based on the best available evidence to date, and highlights areas of practice where evidence is anecdotal or based on retrospective data. Future research as proposed by the London Kawasaki Disease Research Group is outlined, and clinicians are invited to prospectively enrol their suspected cases into this collaborative research project.

Full Text

The Full Text of this article is available as a PDF (139.6 KB).

Figure 1 .

Figure 1

Open in a new tab

Recommended clinical guideline for the management of KD in the UK. *Treatment can be commenced before full 5 days of fever if sepsis excluded; treatment should also be given if the presentation is >10 days from fever onset. **Incomplete cases >1 year old treated at discretion of clinician—seek expert advice. †Refer to paediatric cardiologist. ‡Other specific interventions such as positron emission tomography scanning, addition of calcium channel blocker therapy, and coronary angioplasty at discretion of paediatric cardiologist.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burns J. C., Shike H., Gordon J. B., Malhotra A., Schoenwetter M., Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996 Jul;28(1):253–257. doi: 10.1016/0735-1097(96)00099-x. [DOI] [PubMed] [Google Scholar]
  2. Combes V., Simon A. C., Grau G. E., Arnoux D., Camoin L., Sabatier F., Mutin M., Sanmarco M., Sampol J., Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999 Jul;104(1):93–102. doi: 10.1172/JCI4985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Curtis N., Zheng R., Lamb J. R., Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child. 1995 Apr;72(4):308–311. doi: 10.1136/adc.72.4.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dal Canto A. J., Virgin H. W., 4th Animal models of infection-mediated vasculitis: implications for human disease. Int J Cardiol. 2000 Aug 31;75 (Suppl 1):S37–S52. doi: 10.1016/s0167-5273(00)00187-x. [DOI] [PubMed] [Google Scholar]
  5. Dale R. C., Saleem M. A., Daw S., Dillon M. J. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000 Nov;137(5):723–726. doi: 10.1067/mpd.2000.108444. [DOI] [PubMed] [Google Scholar]
  6. Dhillon R., Newton L., Rudd P. T., Hall S. M. Management of Kawasaki disease in the British Isles. Arch Dis Child. 1993 Dec;69(6):631–638. doi: 10.1136/adc.69.6.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Durongpisitkul K., Gururaj V. J., Park J. M., Martin C. F. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995 Dec;96(6):1057–1061. [PubMed] [Google Scholar]
  8. Etheridge S. P., Tani L. Y., Minich L. L., Revenaugh J. R. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease. Cathet Cardiovasc Diagn. 1998 Nov;45(3):264–268. doi: 10.1002/(sici)1097-0304(199811)45:3<264::aid-ccd10>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  9. Fujita Y., Nakamura Y., Sakata K., Hara N., Kobayashi M., Nagai M., Yanagawa H., Kawasaki T. Kawasaki disease in families. Pediatrics. 1989 Oct;84(4):666–669. [PubMed] [Google Scholar]
  10. Han R. K., Silverman E. D., Newman A., McCrindle B. W. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med. 2000 Jul;154(7):694–699. doi: 10.1001/archpedi.154.7.694. [DOI] [PubMed] [Google Scholar]
  11. Jimenez J. J., Jy W., Mauro L. M., Horstman L. L., Ahn Y. S. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol. 2001 Jan;112(1):81–90. doi: 10.1046/j.1365-2141.2001.02516.x. [DOI] [PubMed] [Google Scholar]
  12. Kato H., Koike S., Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979 Feb;63(2):175–179. [PubMed] [Google Scholar]
  13. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi. 1967 Mar;16(3):178–222. [PubMed] [Google Scholar]
  14. Levin M., Tizard E. J., Dillon M. J. Kawasaki disease: recent advances. Arch Dis Child. 1991 Dec;66(12):1369–1372. doi: 10.1136/adc.66.12.1369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lingam S., Miller C. L., Clarke M., Pateman J. Antibody response and clinical reactions in children given measles vaccine with immunoglobulin. Br Med J (Clin Res Ed) 1986 Apr 19;292(6527):1044–1045. doi: 10.1136/bmj.292.6527.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mancia L., Wahlström J., Schiller B., Chini L., Elinder G., D'Argenio P., Gigliotti D., Wigzell H., Rossi P., Grunewald J. Characterization of the T-cell receptor V-beta repertoire in Kawasaki disease. Scand J Immunol. 1998 Oct;48(4):443–449. doi: 10.1046/j.1365-3083.1998.00415.x. [DOI] [PubMed] [Google Scholar]
  17. Matsubara T., Mason W., Kashani I. A., Kligerman M., Burns J. C. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr. 1996 May;128(5 Pt 1):701–703. doi: 10.1016/s0022-3476(96)80140-5. [DOI] [PubMed] [Google Scholar]
  18. Newburger JW. Kawasaki Disease. Curr Treat Options Cardiovasc Med. 2000 Jun;2(3):227–236. doi: 10.1007/s11936-000-0017-y. [DOI] [PubMed] [Google Scholar]
  19. Shulman S. T., De Inocencio J., Hirsch R. Kawasaki disease. Pediatr Clin North Am. 1995 Oct;42(5):1205–1222. doi: 10.1016/s0031-3955(16)40059-3. [DOI] [PubMed] [Google Scholar]
  20. Siber G. R., Werner B. G., Halsey N. A., Reid R., Almeido-Hill J., Garrett S. C., Thompson C., Santosham M. Interference of immune globulin with measles and rubella immunization. J Pediatr. 1993 Feb;122(2):204–211. doi: 10.1016/s0022-3476(06)80114-9. [DOI] [PubMed] [Google Scholar]
  21. Sireci G., Dieli F., Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol Med. 2000 Jul;6(7):581–590. [PMC free article] [PubMed] [Google Scholar]
  22. Terai M., Shulman S. T. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997 Dec;131(6):888–893. doi: 10.1016/s0022-3476(97)70038-6. [DOI] [PubMed] [Google Scholar]
  23. Weinberg R. S., He L. Y., Alter B. P. Erythropoiesis is distinct at each stage of ontogeny. Pediatr Res. 1992 Feb;31(2):170–175. doi: 10.1203/00006450-199202000-00016. [DOI] [PubMed] [Google Scholar]
  24. Weiss P., Soff G. A., Halkin H., Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res. 1987 Mar 15;45(6):783–790. doi: 10.1016/0049-3848(87)90088-0. [DOI] [PubMed] [Google Scholar]
  25. Wright D. A., Newburger J. W., Baker A., Sundel R. P. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996 Jan;128(1):146–149. doi: 10.1016/s0022-3476(96)70447-x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES